

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tsai et al. Art Unit : Unknown
Serial No. : *Not yet Assigned* Examiner : Unknown
Filed : *Herewith*
Title : METHOD FOR TREATING NEUROPSYCHIATRIC DISORDERS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Under 35 USC §120, this application relies on the earlier filing date of Application Serial No. 09/291,296, filed April 14, 1999, now U.S. Patent No. 6,228,875; Application Serial No. 09/834,351, filed April 13, 2001, now U.S. Patent No. 6,420,351; and Application Serial No. 10/196,686, filed July 15, 2002. The references listed on the enclosed form PTO-1449 were submitted to and/or cited by the Office in the prior applications and/or in U.S. Application Nos. 90/006,227 and 90/006,532, the two pending reexamination applications of U.S. Patent No. 6,228,875. The cited references are therefore not provided in this application.

This statement is being filed with the application. Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney Docket No. 13785-745005.

Respectfully submitted,

Date:

Sept. 23, 2003


Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20728573.doc

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 983 022 615 US

September 23, 2003
Date of Deposit

| | | | | |
|--|--|--|---------------------------------------|-------------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 13785-745005 | Application No. Not yet Assigned |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Tsai <i>et al.</i> | | |
| | | Filing Date Herewith | Group Art Unit Unknown | |

| U.S. Patent Documents | | | | | | | |
|-----------------------|-----------|-------------------|------------------|-------------------------|-------|----------|----------------------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| | AA | 3,873,722 | 3/25/1975 | Smythies | | | |
| | AB | 5,015,740 | 05/14/1991 | Kennis <i>et al.</i> | | | |
| | AC | 5,051,448 | 09/24/1991 | Shashoua | | | |
| | AD | 5,061,721 | 10/29/1991 | Cordi <i>et al.</i> | | | |
| | AE | 5,112,863 | 05/12/1992 | Hashimoto <i>et al.</i> | | | |
| | AF | 5,187,171 | 02/16/1993 | Cordi | | | |
| | AG | 5,260,324 | 11/9/1993 | Cordi <i>et al.</i> | | | |
| | AH | 5,468,763 | 11/21/1995 | Cordi <i>et al.</i> | | | |
| | AI | 5,482,967 | 01/09/1996 | Natsugari <i>et al.</i> | | | |
| | AJ | 5,633,281 | 05/27/1997 | Teall <i>et al.</i> | | | |
| | AK | 5,837,730 | 11/17/1998 | Javitt | | | |
| | AL | 5,854,286 | 12/29/1998 | Javitt <i>et al.</i> | | | |
| | AM | 6,162,827 | 12/19/2000 | Javitt | | | |
| | AN | 6,355,681 | 03/12/2002 | Javitt | | | |
| | AO | 6,361,957 | 03/26/2002 | Javitt | | | |
| | AP | US2002/0161048 A1 | 10/31/2002 | Javitt | | | |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | |
|---|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | AQ | 0 387 867 A1 | 09/19/90 | Europe | | | XX |
| | AR | 0 432 039 A2 | 06/12/91 | Europe | | | XX |
| | AS | 0 652 012 A1 | 05/10/95 | Europe | | | XXX |
| | AT | 0 696 586 A1 | 02/14/96 | Europe | | | XX |
| | AU | JP 08026986A | 01/30/96 | Japan | | | XX |
| | AV | JP 55 020747 A | 02/14/80 | Japan (Abstract) | | | XX |
| | AW | DE 41 17 629 A1 | 12/03/92 | Germany | | | XX |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | | | |
|--|--|--|--|---------------------------------------|-------------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 13785-745005 | Application No. Not yet Assigned | |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Tsai <i>et al.</i> | | | | |
| | | Filing Date Herewith | | Group Art Unit Unknown | | |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| | AX | RU 2096044 C1 | 11/20/97 | Russia | | | XX | |
| | AY | HU P9200192A | 01/27/03 | Hungary | | | | XX |
| | AZ | WO 89/05144 | 06/15/89 | PCT | | | XX | |
| | AAA | WO 97/20552 | 06/12/97 | PCT | | | XX | |
| | ABB | WO 97/20553 | 06/12/97 | PCT | | | XX | |
| | ACC | | | | | | | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|--|
| | ADD | Barnes <i>et al.</i> , "A Rating Scale for Drug-Induced Akathisia" <i>British Journal of Psychiatry</i> 154:672-676, 1989. |
| | AEE | Bart <i>et al.</i> , "Efficacy and Tolerance of D-Cycloserine in Drug-Free Schizophrenic Patients" <i>Biological Psychiatry</i> 40:1298-1300, 1996. |
| | AFF | Baxter <i>et al.</i> , "D-Cycloserine, a Novel Cognitive Enhancer, Improves Spatial Memory in Aged Rats" <i>Neurobiology of Aging</i> 15:207-213, 1994. |
| | AGG | Baxter <i>et al.</i> , "Modulation of the NMDA Receptor Complex by D-Cycloserine" <i>CNS Drug Reviews</i> 1:74-90, 1995. |
| | AHH | Casella <i>et al.</i> , "d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study" <i>Journal of Neural Transmission</i> 95:10-111, 1994. |
| | AII | Chessell <i>et al.</i> , "D-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain" <i>Brain Research</i> 565:345-348, 1991. |
| | AJJ | Contreras, "D-Serine Antagonized Phencyclidine- and MK-801-Induced Stereotyped Behavior and Ataxia" <i>Neuropharmacology</i> 29:291-293, 1990. |
| | AKK | Crane, "Cycloserine as an Antidepressant Agent" <i>The American Journal of Psychiatry</i> 115:1025-1026, 1959. |
| | ALL | Cutler <i>et al.</i> , "The Tolerability and Efficacy of Cycloserine in Alzheimer's Disease" <i>Am. Coll. Neuropsychopharmacol. Annual Meeting</i> , Puerto Rico, 1994. |
| | AMM | D'Souza <i>et al.</i> , "Glycine Site Agonists of the NMDA Receptor: A Review" <i>CNS Drug Reviews</i> 1:227-260, 1995. |
| | ANN | Falk <i>et al.</i> , "A Case Series of D-Cycloserine Added to Donepezil in the Treatment of Alzheimer's Disease" <i>J. Neuropsychiatry Clin. Neurosci.</i> 14:466-467, 2002. |
| | AOO | Fishkin <i>et al.</i> , "D-Cycloserine Attenuates Scopolamine-Induced Learning and Memory Deficits in Rats" <i>Behavioral and Neural Biology</i> 59:150-157, 1993. |
| | APP | Francis <i>et al.</i> , "A Glycine Site as Therapeutic Target" Institute of Neurology, Miriam Marks Department of Neurochemistry; London, WC1N, 1PJ, United Kingdom, pp. 184-188. |
| | AQQ | Goff <i>et al.</i> , "D-Cycloserine Added to Clozapine for Patients With Schizophrenia" <i>Am. J. Psychiatry</i> 153:1628-1630, 1996. |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | |
|--|--|--|---------------------------------------|-------------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 13785-745005 | Application No. Not yet Assigned |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Tsai <i>et al.</i> | | |
| | | Filing Date Herewith | Group Art Unit Unknown | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|---|
| | ARR | Goff <i>et al.</i> , "Dose-Finding Trial of D-Cycloserine Added to Neuroleptics for Negative Symptoms in Schizophrenia" <i>Am. J. Psychiatry</i> 152:1213-1215, 1995. |
| | ASS | Hashimoto <i>et al.</i> , "D-Alanine inhibits methamphetamine-induced hyperactivity in rats" <i>European Journal of Pharmacology</i> 202:105-107, 1991. |
| | ATT | Javitt <i>et al.</i> , "Glycylidodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse" <i>Psychopharmacology</i> 129:96-98, 1997. |
| | AUU | Javitt <i>et al.</i> , "Reversal of Phencyclidine-Induced Hyperactivity by Glycine and the Glycine Update Inhibitor Glycylidodecylamide" <i>Neuropsychopharmacology</i> 17:202-204, 1997. |
| | AVV | Kay <i>et al.</i> , "The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia" <i>Schizophrenia Bulletin National Institute of Mental Health</i> 13:261-276, 1987. |
| | AWW | Kirkpatrick <i>et al.</i> , "The Schedule for the Deficit Syndrome: An Instrument for Research in Schizophrenia" <i>Psychiatry Research</i> 30:119-123, 1989. |
| | AXX | Kumashiro <i>et al.</i> , "Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases" <i>Brain Res.</i> 681:117-125, 1997. |
| | AYY | Leiderman <i>et al.</i> , "Preliminary Investigation of High-Dose Oral Glycine in Serum Levels and Negative Symptoms in Schizophrenia: An Open-Label Trial" <i>Biological Psychiatry</i> , 39:213-215, 1996. |
| | AZZ | Lindenmayer <i>et al.</i> , "Five-Factor Model of Schizophrenia Initial Validation" <i>The Journal of Nervous and Mental Disease</i> 182:631-638, 1994. |
| | AAAA | Lingjaerde <i>et al.</i> , "The UKU side effects rating scale" <i>Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU)</i> ; pp. 81-94, 1986. |
| | ABBB | Malhotra <i>et al.</i> , "NMDA receptor function and human cognition the effects of ketamine in healthy volunteers" <i>Neuropsychopharmacology</i> 14:301-307, 1996. |
| | ACCC | Matsuoka <i>et al.</i> , "D-Cycloserine, a Partial Agonist at the Glycine Site Coupled to N-Methyl-D-aspartate Receptors, Improves Visual Recognition Memory In Rhesus Monkeys" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 278:891-897, 1996. |
| | ADDD | McKhann <i>et al.</i> , "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department ..." <i>Neurology</i> 34:939-944, 1984. |
| | AEEE | Monahan <i>et al.</i> , "Characterization of a [³ H]Glycine Recognition Site as a Modulatory Site of the N-Methyl-D-Aspartate Receptor Complex" <i>Journal of Neurochemistry</i> 53:370-375, 1989. |
| | AFFF | Morrison and Boyd, "Carboxylic Acids," Chapter 23, pp. 822-823, in <i>Organic Chemistry</i> , Fifth ed. Boston: Allyn and Bacon, Inc. |
| | AGGG | Nilsson <i>et al.</i> , "Glycine and D-serine decrease MK-801-induced hyperactivity in mice" <i>J. Neural. Transm</i> 104:1195-1205, 1997. |
| | AHHH | Nishikawa <i>et al.</i> , "PCP-induced abnormal behavior and c-fos gene expression in the brain as indices for neuroleptic-resistant symptoms of schizophrenia" <i>Folia Pharmacologica Japonica</i> , Patent Abstract XP-002117995, 1996. |
| | AIII | Papp <i>et al.</i> , "Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression" <i>European Journal of Pharmacology</i> 316:145-151, 1996. |
| | AJJJ | Patent Abstract; XP-002117996; JP55020747 A; "Antidepressant Drug Low Side Effect Contain Serine Salt Effect Component" 1980. |
| | AKKK | Patent Abstract; XP-002117997; JP08026986; "Anti-phencyclidine drugs contain D-serine esters of formula (I) or their salts as active agents" 1996. |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | |
|--|--|--|---------------------------------------|-------------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 13785-745005 | Application No. Not yet Assigned |
| Information Disclosure Statement by Applicant <small>(Use several sheets if necessary)</small> <small>(37 CFR §1.98(b))</small> | | Applicant Tsai <i>et al.</i> | | |
| | | Filing Date Herewith | Group Art Unit Unknown | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | | |
|---|-----------|--|--|
| Examiner Initial | Desig. ID | Document | |
| | ALLL | Prous <i>et al.</i> , "D-Cycloserine" <i>Drugs of the Future</i> 19: 988-991, 1994. | |
| | AMMM | Ramakers <i>et al.</i> , "The Impaired Long-Term Potentiation in the CA1 Field of the Hippocampus of Cognitive Deficient Microencephalic Rats is Restored by D-Serine" <i>Neuroscience</i> 54:49-60, 1993. | |
| | ANNN | Ramakrishna <i>et al.</i> , "Betaine reverses toxic effects of aluminium: Implications in Alzheimer's disease (AD) and AD-like pathology" <i>Current Science</i> 75:1153-1156, 1998. | |
| | AOOO | Randolph <i>et al.</i> , "D-Cycloserine Treatment of Alzheimer Disease" <i>Alzheimer Disease and Associate Disorders</i> 8:198-205, 1994. | |
| | APPP | Riekkinen <i>et al.</i> , "The Effects of D-Cycloserine on Cognition in Experimental Models of Alzheimer's Disease" <i>Neurology</i> 43:A292; Abstract XP-0021178979. | |
| | AQQQ | Rimland, "Dimethylglycine (DMG), a nontoxic metabolite, and autism"; <i>Editor's Notebook</i> ; Abstract XP-002117993. | |
| | ARRR | Rockstroh <i>et al.</i> , "Effects of the Novel NMDA receptor antagonist SDZ EAA 494 on memory and attention in humans" <i>Psychopharmacology</i> 124:261-266, 1996. | |
| | ASSS | Rosen <i>et al.</i> , "A new rating scale for Alzheimer's Disease" <i>The American Journal of Psychiatry</i> 141:1356-1364, 1984. | |
| | ATTT | Russell, "A Multiple scoring method for the assessment of complex memory functions" <i>Journal of Consulting and Clinical Psychology</i> 43:800-809, 1975. | |
| | AUUU | Schuster <i>et al.</i> , "D-Cycloserine reverse the working memory impairment of hippocampal-lesioned rats in a spatial learning task" <i>European Journal of Pharmacology</i> 224:97-98, 1992. | |
| | AVVV | Simeon <i>et al.</i> , "d-Cycloserine Therapy of Psychosis by Symptom Provocation" <i>Comprehensive Psychiatry</i> 11:80-88, 1970. | |
| | AWWW | Simpson <i>et al.</i> , "A Rating Scale for Extrapyramidal Side Effects" <i>Acta Psychiatr. Scand. Suppl.</i> 212:11-19, 1970. | |
| | AXXX | Sirvio <i>et al.</i> , "D-Cycloserine, a modulator of the N-methyl-D-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist" <i>Neuroscience Letters</i> 146:215-218, 1992. | |
| | AYYY | Tanii <i>et al.</i> , "Effects of Allosteric Agonists for NMDA Receptor and Their Derivatives on PCP-Induced Abnormal Behaviors in Rat" National Institute of Neuroscience, NCNP, Kodaira; XP-002117991; Vol. 44, 1990. | |
| | AZZZ | Tanii <i>et al.</i> , "Stereoselective Antagonism by Enantiomers of Alanine and Serine of Phencyclidine-Induced Hyperactivity, Stereotypy and Ataxia in the Rat" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 269:1040-1048, 1994. | |
| | AAAAA | Temple <i>et al.</i> , "Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury" <i>Brain Research</i> 741: 246-251, 1996. | |
| | ABBBB | Tsai <i>et al.</i> , "A Preliminary Study of D-Cycloserine Treatment in Alzheimer's Disease" <i>The Journal of Neuropsychiatry</i> 10:224-226, 1998. | |
| | ACCCC | Tsai <i>et al.</i> , "Improved cognition in Alzheimer's Disease with Short-Term D-Cycloserine Treatment" <i>Am. J. Psychiatry</i> 156:467-469, 1999. | |
| | ADDDD | Vamvakides, "Nootropic activity of glycinergic derivatives in relation to their dualistic effects on cerebral monoamines" <i>Boll. Chim. Farm.</i> 133:369-373, 1994. | |
| | AEEEE | van Berckel <i>et al.</i> , "Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients" <i>Biol. Psychiatry</i> 40:1298-1300, 1996. | |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |